Tirzepatide
Dual GIP/GLP-1 Receptor Agonist
A novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.
Overview
Tirzepatide is a novel dual GIP and GLP-1 receptor agonist. It is a 39-amino acid synthetic peptide that activates both incretin hormone receptors simultaneously. Research has investigated its effects on glycemic control, body weight, and metabolic parameters.
Research Information
Research on tirzepatide has focused on its unique dual-agonist mechanism. Studies suggest simultaneous activation of both GIP and GLP-1 receptors may produce additive or synergistic effects on insulin secretion, glucagon suppression, and appetite regulation.
Research Dosage Reference
Research protocols begin with lower doses and escalate over time. Standard vials contain 5mg lyophilized powder. All dosing information is for research reference only.
Related Research
Disclaimer: All information provided is for educational and research purposes only. This is not medical advice. These compounds are not approved for human use. Always consult with qualified professionals before conducting research.